CASI Pharmaceuticals Inc (NASDAQ:CASI)
| 1.94 Delayed Data As of 3:59pm ET |  +0.03 / +1.57%Today’s Change | 1.15 Today|||52-Week Range 3.82 | -37.22% Year-to-Date |
Latest CASI News | Press Releases
| Week In Review: BeiGene Signs $540 Million Deal For China Rights To 3 HBV Candidates Jul 26 / Seeking Alpha - Paid Partner Content | CASI Pharma +11.9% as CEO buys nearly $7.9M in shares Jul 24 / Seeking Alpha - Paid Partner Content |
| CASI Pharma +11.9% as CEO buys nearly $7.9M worth Jul 24 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 1.91 |
| Today’s open | 1.89 |
| Day’s range | 1.89 - 2.04 |
| Volume | 22,899 |
| Average volume (3 months) | 346,479 |
| Market cap | $228.5M |
Data as of 3:59pm ET, 08/11/2020
Growth & Valuation
| Earnings growth (last year) | -48.04% |
| Earnings growth (this year) | +37.87% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 71.77 |
| Price/Book | 2.53 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AQSTAquestive Therapeuti... | -0.37 | -5.32% |
| MISTMilestone Pharmaceut... | -0.58 | -6.12% |
| AGRXAgile Therapeutics I... | -0.09 | -3.35% |
| EVLOEvelo Biosciences In... | +0.10 | +2.04% |
Data as of 4:23pm ET, 08/11/2020
Financials
| Next reporting date | November 17, 2020 |
| EPS forecast (this quarter) | -$0.08 |
| Annual revenue (last year) | $4.1M |
| Annual profit (last year) | -$46.0M |
| Net profit margin | -1,114.31% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Rockville, Maryland |
Forecasts
